{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:49:59Z","timestamp":1788432599397,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgery"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.surg.2020.06.038","type":"journal-article","created":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T07:54:23Z","timestamp":1597737263000},"page":"629-635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cost-effectiveness analysis of universal germline testing for patients with pancreatic cancer"],"prefix":"10.1016","volume":"169","author":[{"given":"Ashley N.","family":"Krepline","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Geurts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9364-2712","authenticated-orcid":false,"given":"Mandana","family":"Kamgar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srivats","family":"Madhavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth A.","family":"Erickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael O.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.surg.2020.06.038_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.5963","article-title":"An emerging paradigm for germline testing in pancreatic ductal adenocarcinoma and immediate implications for clinical practice [e-pub ahead of print]","author":"Rainone","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.surg.2020.06.038_bib2","first-page":"70","article-title":"A\u00a0practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment","volume":"17","author":"Hampel","year":"2015","journal-title":"Gen Med"},{"key":"10.1016\/j.surg.2020.06.038_bib3","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1001\/jama.2018.6228","article-title":"Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer","volume":"319","author":"Hu","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.surg.2020.06.038_bib4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.surg.2020.06.038_bib5","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/jnci\/djn103","article-title":"Cost of care for elderly cancer patients in the United States","volume":"100","author":"Yabroff","year":"2008","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.surg.2020.06.038_bib6","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2471\/BLT.15.164418","article-title":"Cost-effectiveness thresholds: pros and cons","volume":"94","author":"Bertram","year":"2016","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.surg.2020.06.038_bib7","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1002\/cam4.3011","article-title":"Treatment patterns and outcomes in pancreatic cancer: retrospective claims analysis","volume":"9","author":"Doleh","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.surg.2020.06.038_bib8","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1634\/theoncologist.2018-0114","article-title":"Neoadjuvant FOLFIRINOX for patients with borderline resectable or locally advanced pancreatic cancer: results of a decision analysis","volume":"24","author":"Choi","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.surg.2020.06.038_bib9","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1002\/cncr.27490","article-title":"Costs and trends in pancreatic cancer treatment","volume":"118","author":"O\u2019Neill","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.surg.2020.06.038_bib10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ygyno.2015.08.013","article-title":"PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis","volume":"139","author":"Smith","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.surg.2020.06.038_bib11","first-page":"1219","article-title":"Cost-effectiveness of niraparib and olaparib as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer","volume":"24","author":"Zhong","year":"2018","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.surg.2020.06.038_bib12","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1200\/JCO.2007.15.8782","article-title":"Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005)","volume":"26","author":"Corsini","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.surg.2020.06.038_bib13","doi-asserted-by":"crossref","unstructured":"Truty MJ, Kendrick ML, Nagorney DM, et al. Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline\/locally advanced pancreatic cancer [e-pub ahead of print]. Ann Surg. https:\/\/doi.org\/10.1097\/SLA.0000000000003284. Accessed October 20, 2019.","DOI":"10.1097\/SLA.0000000000003284"},{"key":"10.1016\/j.surg.2020.06.038_bib14","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.surg.2020.06.038_bib15","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1200\/JCO.2015.64.0730","article-title":"Benefit of surveillance for pancreatic cancer in high-risk individuals: outcome of long-term prospective follow-up studies from three european expert centers","volume":"34","author":"Vasen","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.surg.2020.06.038_bib16","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1186\/s12885-018-4610-4","article-title":"Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades: a SEER-based study","volume":"18","author":"Saad","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.surg.2020.06.038_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/djy024","article-title":"Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms","volume":"110","author":"Lowery","year":"2018","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.surg.2020.06.038_bib18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1158\/1055-9965.EPI-15-0455","article-title":"Prevalence of pathogenic mutations in cancer predisposition genes among pancreatic cancer patients","volume":"25","author":"Hu","year":"2016","journal-title":"Cancer Epidemiol. Biomarkers Prev"},{"key":"10.1016\/j.surg.2020.06.038_bib19","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1200\/JCO.2017.72.3502","article-title":"Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma","volume":"35","author":"Shindo","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.surg.2020.06.038_bib20","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1002\/cncr.29664","article-title":"Identification of germline genetic\u00a0mutations in patients with pancreatic cancer","volume":"121","author":"Salo-Mullen","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.surg.2020.06.038_bib21","first-page":"1","article-title":"Multigene hereditary cancer panels reveal\u00a0high-risk pancreatic cancer susceptibility genes","volume":"2","author":"Hu","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.surg.2020.06.038_bib22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41436-018-0009-5","article-title":"Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer","volume":"21","author":"Yurgelun","year":"2019","journal-title":"Genet Med"},{"key":"10.1016\/j.surg.2020.06.038_bib23","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/gim.2014.153","article-title":"BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: A PACGENE study","volume":"17","author":"Zhen","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.surg.2020.06.038_bib24","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1245\/s10434-007-9384-x","article-title":"A\u00a0randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: Gemcitabine alone versus gemcitabine combined with cisplatin","volume":"14","author":"Palmer","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2020.06.038_bib25","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1200\/JCO.19.02274","article-title":"Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC Trial","volume":"38","author":"Versteijne","year":"2020","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606020304335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606020304335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T10:56:40Z","timestamp":1758538600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039606020304335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0039606020304335"],"URL":"https:\/\/doi.org\/10.1016\/j.surg.2020.06.038","relation":{},"ISSN":["0039-6060"],"issn-type":[{"value":"0039-6060","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness analysis of universal germline testing for patients with pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.surg.2020.06.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}